Tropical diseases

NLR launches innovative research project to end leprosy transmission in India

Retrieved on: 
Monday, October 5, 2020
Infectious diseases, Medical specialties, Tropical diseases, Leprosy, RTT, Clinical medicine, Lepra

A new enhanced preventive treatment distributed in Uttar Pradesh, districts Chandauli and Fatehpur

Key Points: 
  • A new enhanced preventive treatment distributed in Uttar Pradesh, districts Chandauli and Fatehpur
    AMSTERDAM, Oct. 5, 2020 /PRNewswire/ -- NLR and NLR India hosted the official start of the innovative project 'Stop the Transmission of Leprosy!'
  • Project , focuses on early detection of leprosy and preventive treatment of people who have frequent and close contact with persons affected by leprosy.
  • Theproject, designed by NLR in collaboration with national stakeholders, aims to stop the transmission of leprosy by using a package of innovative tools and best practices.
  • NLR takes pride in enabling research and driving evidence-based innovation to achieve zero transmission, zero disability and zero discrimination due to leprosy.

Public Health Notice: Outbreak of Salmonella infections linked to red onions imported from the United States

Retrieved on: 
Thursday, October 1, 2020
Infectious diseases, Medical specialties, Organisms, Tropical diseases, Zoonoses, Disease outbreak, Epidemiology, Salmonella, Onion

Onions imported from the United States are no longer under investigation.

Key Points: 
  • Onions imported from the United States are no longer under investigation.
  • Given that Salmonella illness reporting linked to this outbreak has significantly decreased over the last three weeks, the outbreak appears to be over and the investigation has been closed.
  • Investigation findings identified exposure to red onions imported from the USA as a likely source of the outbreak.
  • Many of the ill individuals reported having eaten red onions before getting sick.

Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

Retrieved on: 
Tuesday, September 29, 2020
Infectious diseases, Medical specialties, Leishmaniasis, Tropical diseases, Ajinomoto, Cutaneous leishmaniasis

"We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.

Key Points: 
  • "We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.
  • "We are very pleased to be partnering with Ajinomoto Bio-Pharma Services for the supply of promising new therapeutic for the treatment of cutaneous leishmaniasis," said Dr Byron Arana, Head of Cutaneous Leishmaniasis Programme at DNDi.
  • "With this partnership, we continue our goal to develop and provide safe and effective cutaneous leishmaniasis therapeutics."
  • Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client's needs.

Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

Retrieved on: 
Tuesday, September 29, 2020
Infectious diseases, Medical specialties, Leishmaniasis, Tropical diseases, Ajinomoto, Cutaneous leishmaniasis

"We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.

Key Points: 
  • "We are excited to be able to collaborate on this oligonucleotide with DNDi and support them in their efforts to develop and supply this quality of life improving therapeutic for people with leishmaniasis," said Noriyasu Kataoka, Quality Manager & President, Ajinomoto Bio-Pharma Services Osaka.
  • "We are very pleased to be partnering with Ajinomoto Bio-Pharma Services for the supply of promising new therapeutic for the treatment of cutaneous leishmaniasis," said Dr Byron Arana, Head of Cutaneous Leishmaniasis Programme at DNDi.
  • "With this partnership, we continue our goal to develop and provide safe and effective cutaneous leishmaniasis therapeutics."
  • Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client's needs.

GHIT Fund Announces New Investments: A Total of 1.37 Billion Yen in Drugs for Malaria, Chagas Disease, Leishmaniasis, Schistosomiasis, and Soil-Transmitted Helminths, and Diagnostics for Malaria, Buruli Ulcer, and Schistosomiasis

Retrieved on: 
Tuesday, September 29, 2020
Medical specialties, Infectious diseases, Microbiology, Bacterial diseases, Tropical diseases, Neglected tropical diseases, RTT, Buruli ulcer, Bacteriology, Ulcer, Mycobacterium

Buruli ulcer is a cutaneous mycobacterial infection, which is reported in about 2,000 new patients annually worldwide, mainly in West Africa.

Key Points: 
  • Buruli ulcer is a cutaneous mycobacterial infection, which is reported in about 2,000 new patients annually worldwide, mainly in West Africa.
  • We have established a method for amplifying M. ulcerans DNA without using expensive equipment and a determination method by DNA chromatography.
  • We will combine these techniques to develop a new diagnostic method for Buruli ulcer.
  • In this project, we will develop a diagnostic kit for Buruli ulcer that can be tested by anyone in anywhere.

Global WholeHealth Partners Corp. (GWHP) Announces It Had Submitted an Emergency Use Authorization (EUA) Application # PEUA201789 Date 09/14/2020: for the Global Antigen CoViD19 SARS2 Rapid Test as Mentioned in the 8K Filing on 09/15/20

Retrieved on: 
Thursday, September 17, 2020
Medicine, Medical specialties, Infectious diseases, Tropical diseases, Zoonoses, Medical terminology, Medical tests, West African Ebola virus epidemic, Emergency Use Authorization, Rapid diagnostic test, Ebola, Dengue fever

Global WholeHealth Partners Corp. (OTC MKTS: GWHP) announced today that an application for Emergency Use Authorization (EUA) under the PreEUA is under review at the U.S. Food and Drug Administration (FDA) for Global Antigen CoViD19 SARS2 Rapid Test.

Key Points: 
  • Global WholeHealth Partners Corp. (OTC MKTS: GWHP) announced today that an application for Emergency Use Authorization (EUA) under the PreEUA is under review at the U.S. Food and Drug Administration (FDA) for Global Antigen CoViD19 SARS2 Rapid Test.
  • For international testing, which is not sold in the USA, but has a Certificate of Exportability by theFDA Certificate No.
  • 2260-11-2019, are tests likeRapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.
  • Global is also selling theIgG/IgM Antibody Rapid Test for Covid-19as Global has partnered with Healgen which has received its FDA EUA Authorization.

Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

Retrieved on: 
Tuesday, September 15, 2020
Medical specialties, Animal diseases, Veterinary medicine, Biological weapons, Tropical diseases, Zoonoses, Animal virology, Ebolavirus, Sudan ebolavirus, Filoviridae, Ebola, Zaire ebolavirus

These most recent results demonstrate the thermostabilization of three virus glycoproteins (from Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus), and the identification of key stability-indicating assays to further support mono-, bi- and tri-valent vaccine formulations.

Key Points: 
  • These most recent results demonstrate the thermostabilization of three virus glycoproteins (from Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus), and the identification of key stability-indicating assays to further support mono-, bi- and tri-valent vaccine formulations.
  • "The continued advances in the filovirus program demonstrates the program's maturity and overall developability," noted Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix.
  • "The compatibility with thermostabilization, and the identification of key stability indicating assays, are both hallmarks of a potentially broadly applicable vaccine platform.
  • Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Global Malaria Diagnostics Market Report 2020-2025 - Microscopic Diagnostics Expected to Hold the Largest Market Share

Retrieved on: 
Friday, August 28, 2020
Infectious diseases, Medical specialties, Tropical diseases, Malaria, RTT

DUBLIN, Aug. 28, 2020 /PRNewswire/ -- The "Malaria Diagnostics Market - Growth, Trends, and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 28, 2020 /PRNewswire/ -- The "Malaria Diagnostics Market - Growth, Trends, and Forecast (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
  • The global malaria diagnostics market is expected to register a CAGR of 4.5% over the forecast period.
  • In addition, the rising need for the early detection and increased awareness regarding malaria diagnosis is expected to propel the demand for the malaria diagnostics market in this region.
  • With the rising prevalence of diseases, a few other smaller players are also expected to enter into the market and hold a substantial share.

Connectyx Technologies Holdings Group, Inc. Announces Strategic Relationship with Mid-Atlantic BioTherapeutics, Inc. for Treatment of Symptomatic Rabies

Retrieved on: 
Thursday, August 27, 2020
Medical specialties, Infectious diseases, Clinical medicine, Tropical diseases, Neglected tropical diseases, Vaccination, Vaccine, Virology, Rabies

IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can be treated by the existing approved rabies vaccines.

Key Points: 
  • IMT504 is being developed to treat patients whose disease has progressed beyond the stage where it can be treated by the existing approved rabies vaccines.
  • This strategic relationship provides an example of how the Company plans to grow our rare diseases product pipeline through a combination of acquisitions, in-licensing and sub-licensing of new technologies.
  • About Connectyx Technologies Holdings Group, Inc. http://connectyx.com/
    Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases.
  • Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines

Retrieved on: 
Thursday, August 13, 2020
Medical specialties, Infectious diseases, Animal diseases, Tropical diseases, Zoonoses, Biological weapons, Sudan ebolavirus, Ebolavirus, Zaire ebolavirus, Filoviridae, Ebola, Marburg virus disease

ATLANTA, GA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today a multi-party collaboration for the development of Sudan ebolavirus (SUDV) and Marburg virus (MARV) vaccine candidates.

Key Points: 
  • ATLANTA, GA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today a multi-party collaboration for the development of Sudan ebolavirus (SUDV) and Marburg virus (MARV) vaccine candidates.
  • David Dodd, GeoVax President and CEO, commented, This exciting collaboration enables us to advance these two critically needed vaccine candidates through nonhuman primate testing.
  • Sudan ebolavirus (SUDV) is one of six known viruses within the genus Ebolavirus (Filoviridae family) and causes Ebola virus disease in humans, with a fatality rate as high as 71%.
  • GeoVaxs current development programs are focused on preventive vaccines against COVID-19, HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against solid tumor cancers.